Open House Originale rebate agreements for Dapagliflozin
Originaltitel der Bekanntmachung
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-07 - Dapagliflozin
Opportunity Score
Warum diese Bewertung?
Chance
56 / 100
Komplexität
48 / 100
Risikofaktoren
Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...
Only pharmaceutical entrepreneurs meeting the AMG and authorisation conditions may participate.
Submission deadline in 5 days
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Überblick
Moderate opportunityWichtige Fakten
- Supplies contract
- 1 lot
- Duration until Aug 2026
- Conclusion of rebate agreements for the medicinal product Dapagliflozin under Section 130c SGB V.
- Uniform Open House terms apply; no individual negotiation of contract content.
Vollständige Zusammenfassung anzeigen
Open House supply arrangement for Dapagliflozin pharmaceutical products in Germany, led by Techniker Krankenkasse with participating sickness funds. It is not a classic public procurement award procedure; contracts are concluded on uniform terms with all eligible pharmaceutical companies that meet the stated conditions. No contract value is stated. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and documents are only provided electronically to eligible companies.
Risiken
Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...
Only pharmaceutical entrepreneurs meeting the AMG and authorisation conditions may participate.
Submission deadline in 5 days
Analyse kann unvollständig sein
Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.
Wichtige Anforderungen
Technical
- Applicant must be a pharmaceutical entrepreneur within the meaning of Section 4(18) AMG for the relevant medicinal product.
- Applicant must have its seat in the scope of the AMG, another EU Member State, or another EEA state.
- Applicant must hold a valid marketing authorisation for the relevant medicinal product or otherwise be entitled to place it on the market in its own name.
Zuschlagskriterien
Lot 1
Auftraggeber
Ort
Hamburg, DEU
Website
Kennung
992-80116-93
Tätigkeit
Health
Lose (1)
LOT-0001
Open House Originale rebate agreements for Dapagliflozin
Open House contract for rebate agreements under Section 130c SGB V for the active substance Dapagliflozin. Scope is nationwide in Germany. The lot information comes from structured data and the notice text. No lot value is stated. The procedure is open to eligible pharmaceutical companies during the contract period.
Ort
Dauer
Kategorie
Zuschlagskriterien
Frist
Zuschlagsdetails
Participation and suitability requirements in the Open House procedure
Hinweis zum Wert
Originale TED-Daten anzeigen
Originaler Los-Titel
Open House Originale Rabattverträge 2024-07 - Dapagliflozin
Originale TED-Beschreibung
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c SGB V zum Wirkstoff Dapagliflozin zu schließen.
Vergabedetails
- Veröffentlichungsdatum
- 19 Jul 2024
- Sprachen
- German
Referenzmetadaten
- Rechtsgrundlage
- 32014L0024
Referenz-IDs
- Ausschreibungs-ID
- 434034-2024
Dokumente (1)
Ähnliche Ausschreibungen
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Opportunity Score
Warum diese Bewertung?
Chance
56 / 100
Komplexität
48 / 100
Risikofaktoren
Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...
Only pharmaceutical entrepreneurs meeting the AMG and authorisation conditions may participate.
Submission deadline in 5 days
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications